Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials

Overview

Journal Ochsner J

Specialty General Medicine

Date 2021 Jan 7

PMID 33408570

Authors

Alaa A Abd-Elsayed

David Hao

Robert Chu

Ivan Urits

Omar Viswanath

Vwaire Orhurhu

Affiliations

Soon will be listed here.

References

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L . [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):215-219. PMC: 8800713. DOI: 10.3785/j.issn.1008-9292.2020.03.03. View

Skipper C, Pastick K, Engen N, Bangdiwala A, Abassi M, Lofgren S . Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med. 2020; 173(8):623-631. PMC: 7384270. DOI: 10.7326/M20-4207. View

Boulware D, Pullen M, Bangdiwala A, Pastick K, Lofgren S, Okafor E . A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; 383(6):517-525. PMC: 7289276. DOI: 10.1056/NEJMoa2016638. View

Voss A, Coombs G, Unal S, Saginur R, Hsueh P . Publishing in face of the COVID-19 pandemic. Int J Antimicrob Agents. 2020; 56(1):106081. PMC: 7357502. DOI: 10.1016/j.ijantimicag.2020.106081. View

Rosendaal F . Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. Int J Antimicrob Agents. 2020; 56(1):106063. PMC: 7357515. DOI: 10.1016/j.ijantimicag.2020.106063. View

Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M . Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(4):e208857. DOI: 10.1001/jamanetworkopen.2020.8857. View

Mitja O, Corbacho-Monne M, Ubals M, Tebe C, Penafiel J, Tobias A . Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clin Infect Dis. 2020; 73(11):e4073-e4081. PMC: 7454406. DOI: 10.1093/cid/ciaa1009. View

Chen C, Lin Y, Chen T, Tseng T, Wong H, Kuo C . A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020; 15(12):e0242763. PMC: 7710068. DOI: 10.1371/journal.pone.0242763. View

Cavalcanti A, Zampieri F, Rosa R, Azevedo L, Veiga V, Avezum A . Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020; 383(21):2041-2052. PMC: 7397242. DOI: 10.1056/NEJMoa2019014. View

10.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View